Countdown to clear

AND GET CLEARER-LOOKING SKIN OR YOUR MONEY BACK^

We're so confident in Effaclar Duo [+] that if you don't see results we'l give you your money back^

START YOUR COUNTDOWN
Effaclar Duo [+] Clearer skin or your money back. Click here for details

POSSIBLY THE LAST
ANTI-BLEMISH CREAM
YOU'LL EVER TRY

New And Improved Benefits

  • One product does it all

    One product does it all

    Clinically proven to correct the appearance of blemishes, new Effaclar DUO [+] also helps pores look less clogged, makes skin texture feel smoother and fights against marks.

  • New anti-mark action

    New anti-mark action

    NEW Effaclar DUO [+] helps to reduce the appearance of red and brown marks - a consequence of blemishes which can affect anyone.

  • Pore unclogging

    Pore unclogging

    Enjoy smoother, clearer-looking skin as new Effaclar DUO [+] moisturises and removes dirt and bacteria which may lead to spots.

  • Use day and night

    Use day and night

    A hydrating, non-sticky, gel-cream texture, new Effaclar DUO [+] should be applied over your entire face before you apply make-up day and night.

  • Suitable for sensitive skin

    Suitable for sensitive skin

    NEW Effaclar DUO [+] is specifically developed for daily use, even on sensitive skin. It is also suitable for acne-prone skin.

Tried, Tested, Loved

EFFACLAR DUO IS NOW EVEN BETTER, BUT SEE WHAT BLOGGERS AND FANS HAD TO SAY ABOUT THE ORIGINAL...

What did you think?

Read full terms & conditions of use

Discover the Effaclar range

Choose from all of our products for oily, blemish-prone skin to complete your routine.

View the entire range

What the experts say

  • How to use Effaclar Duo [+]

    Effaclar Duo [+] as part of your skincare routine.

    View article

  • Makeup and oily skin

    Discover the best routine for blemish-prone skin.

    View article

  • Blemish-prone skin

    How acne develops and how to treat it.

    View article

  • An interview with Dr Tabi Leslie

    Dr Tabi Leslie on adult acne.

    View article